Lipigon Pharmaceuticals AB (publ) (FRA:9RP)

Market Cap	690.20K -57.1%
Revenue (ttm)	119.12K -85.3%
Net Income	-3.25M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3,905
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0001 - 0.0241
Beta	n/a
RSI	46.81
Earnings Date	Feb 20, 2026

About FRA:9RP

Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia. The company has a license agreement with Leader...

• Industry: Pharmaceutical Preparations
• Founded: 2010
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9RP

Financial Performance

In 2024, FRA:9RP's revenue was 10.29 million, a decrease of -37.30% compared to the previous year's 16.41 million. Losses were -25.26 million, 108.3% more than in 2023.

Financial numbers in SEK